Evidence map›Paper›PMID 42406716›Full record

ArticleJournal of medicinal chemistry2026

Landscaping the Nitazene Scaffold to Identify Novel Mu-Opioid Receptor Modulators: From Molecular Design and Chemical Synthesis to Pharmacological Profiling.

Neha Upadhyay, Logan T Neel, Ennian Li, Abeje A Silte, Rui Lyu, Dana E Selley, William L Dewey, Yan Zhang, Piyusha P Pagare

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Neha UpadhyayDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia23298, United States.
Logan T NeelDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia23298, United States.ORCID 0000-0002-4685-2300
Ennian LiDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia23298, United States.ORCID 0000-0002-6761-7713
Abeje A SilteDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia23298, United States.ORCID 0000-0002-7312-0818
Rui LyuDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia23298, United States.
Dana E SelleyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia23298, United States.
William L DeweyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia23298, United States.
Yan ZhangDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia23298, United States.ORCID 0000-0001-8934-7016
Piyusha P PagareDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia23298, United States.ORCID 0000-0002-4848-2673

Funding

Mu Opioid Receptor Modulator Development to Treat Opioid Use DisorderUH3DA050311 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ZHANG, YAN · 2023 to 2025
$4.3M
Novel Mu Opioid Receptor Modulators to Counteract Synthetic OpioidsDP1DA063098 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Piyusha P Pagare · 2025 to 2026
$932k
NIDA NIH HHS DP1 DA063098NIDA NIH HHS UH3 DA050311
6 · The paper itself

Abstract

The surge in ultrapotent synthetic opioids has intensified the need for new chemical strategies for modulating the mu-opioid receptor (MOR). In this study, nitazene scaffold, a chemically distinct and underexplored chemotype, was utilized as an underexplored framework for MOR modulation. Structure-activity relationship studies were conducted through modifications at three key positions of the nitazene core and evaluated for MOR binding, in vitro functional, and in vivo behavioral activities. Among them, compound

Indexed as

Analgesics, OpioidDrug DesignReceptors, Opioid, muAnimalsBenzimidazolesHumansMiceModels, MolecularStructure-Activity RelationshipAnalgesics, OpioidBenzimidazolesnitazeneReceptors, Opioid, mu

Identifiers

PMID42406716
PMCPMC13403233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.